Engineered Branaplam Aptamers Exploit Structural Elements from Natural Riboswitches
Open Access
- 2 July 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 19 (7) , 1447-1452
Abstract
Drug candidates that fail in clinical trials for efficacy reasons might still have favorable safety and bioavailability characteristics that could be exploited. A failed drug candidate could be repurposed if a receptor, such as an aptamer, were created that binds the compound with high specificity. Branaplam is a small molecule that was previously in development to treat spinal muscular atrophy and Huntington's disease. Here, we report the development of a small (48-nucleotide) RNA aptamer for branaplam with a dissociation constant of similar to 150 nM. Starting with a combinatorial RNA pool integrating the secondary and tertiary structural scaffold of a Guanine-I riboswitch aptamer interspersed with regions of random sequence, in vitro selection yielded aptamer candidates for branaplam. Reselection and rational design were employed to improve binding of a representative branaplam aptamer candidate. A resulting variant retains the pseudoknot and two of the paired elements (P2 and P3) from the scaffold but lacks the enclosing paired element (P1) that is essential for the function of the natural Guanine-I riboswitch aptamer. A second combinatorial RNA pool based on the scaffold for TPP (thiamin pyrophosphate) riboswitches also yielded a candidate offering additional opportunities for branaplam aptamer development.Keywords
Funding Information
- Howard Hughes Medical Institute
- Life Sciences Research Foundation
- National Institutes of Health (T32 GM067543)
This publication has 44 references indexed in Scilit:
- SMA - TREATMENTNeuromuscular Disorders, 2021
- Aptamers in RNA-based switches of gene expressionCurrent Opinion in Biotechnology, 2020
- A Capture-SELEX Strategy for Multiplexed Selection of RNA Aptamers Against Small Molecules2017
- Safety and efficacy findings in the first-in-human trial (FIH) of the oral splice modulator branaplam in type 1 spinal muscular atrophy (SMA): interim resultsNeuromuscular Disorders, 2017
- In vitro selection and amplification protocols for isolation of aptameric sensors for small moleculesMethods, 2016
- RNA aptamers as genetic control devices: The potential of riboswitches as synthetic elements for regulating gene expressionBiotechnology Journal, 2015
- In-Line Probing Analysis of Riboswitches2008
- In Vitro Selection of Structure‐Switching Signaling AptamersAngewandte Chemie International Edition, 2005
- Altering molecular recognition of RNA aptamers by allosteric selectionJournal of Molecular Biology, 2000
- Structure, recognition and adaptive binding in RNA aptamer complexesJournal of Molecular Biology, 1997